A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands
Open accessAbstract
// Tai Qin 1, 2 , Lindsey Barron 1 , Lu Xia 1, 3 , Haojie Huang 5 , Maria M. Villarreal 4 , John Zwaagstra 9 , Cathy Collins 9 , Junhua Yang 1 , Christian Zwieb 4 , Ravindra Kodali 8 , Cynthia S. Hinck 8 , Sun Kyung Kim 4 , Robert L. Reddick 6 , Chang Shu 2 , Maureen D. O’Connor-McCourt 9 , Andrew P. Hinck 8 , Lu-Zhe Sun 1, 7 1 Department of Cell Systems and Anatomy, University of Texas Health Science Center, San Antonio, TX, USA 2 Department of Vascular Surgery, Second Xiangya Hospital and Xiangya School of Medicine, Central South University, Hunan, China 3 Department of Gynecology and Obstetrics, Xiangya Hospital and Xiangya School of Medicine, Central South University, Hunan, China 4 Department of Biochemistry, University of Texas Health Science Center, San Antonio, TX, USA 5 Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA 6 Department of Pathology, University of Texas Health Science Center, San Antonio, TX, USA 7 Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, Texas, USA 8 Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA USA 9 National Research Council Human Health Therapeutics Portfolio, Montréal, Quebec, Canada, Maureen O'Connor-McCourt is currently affiliated with Formation Biologics, Montréal, Quebec, Canada Correspondence to: Lu-Zhe Sun, email: SUNL@uthscsa.edu Andrew P. Hinck, email: ahinck@pitt.edu Keywords: TGF-β trap, RER, tumorigenesis, Pten, prostate cancer Received: August 15, 2016 Accepted: November 07, 2016 Published: November 14, 2016 ABSTRACT The effects of transforming growth factor beta (TGF-β) signaling on prostate tumorigenesis has been shown to be strongly dependent on the stage of development, with TGF-β functioning as a tumor suppressor in early stages of disease and as a promoter in later stages. To study in further detail the paradoxical tumor-suppressive and tumor-promoting roles of the TGF-β pathway, we investigated the effect of systemic treatment with a TGF-β inhibitor on early stages of prostate tumorigenesis. To ensure effective inhibition, we developed and employed a novel trivalent TGF-β receptor trap, RER, comprised of domains derived from the TGF-β type II and type III receptors. This trap was shown to completely block TβRII binding, to antagonize TGF-β1 and TGF-β3 signaling in cultured epithelial cells at low picomolar concentrations, and it showed equal or better anti-TGF-β activities than a pan TGF-β neutralizing antibody and a TGF-β receptor I kinase inhibitor in various prostate cancer cell lines. Systemic administration of RER inhibited prostate tumor cell proliferation as indicated by reduced Ki67 positive cells and invasion potential of tumor cells in high grade prostatic intraepithelial neoplasia (PIN) lesions in the prostate glands of Pten conditional null mice. These results provide evidence that TGF-β acts as a promoter rather than a suppressor in the relatively early stages of this spontaneous prostate tumorigenesis model. Thus, inhibition of TGF-β signaling in early stages of prostate cancer may be a novel therapeutic strategy to inhibit the progression as well as the metastatic potential in patients with prostate cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The Fc-TβRII trap was the basis for the development of a bi-specific trap that combines TGF-β binding by the TβRII ectodomains with a human PD-L1-blocking IgG1.
“The Fc-TβRII trap was also the basis for the development of a bi-specific trap that combines TGF-β binding by the TβRII ectodomains with a human PD-L1-blocking IgG1308,309,312.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [312]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181 · see citing works
TGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804 · see citing works
Mechanism of activation of the TGF-β receptor
Wrana, J. L., Attisano, L., Wieser, R., Ventura, F., & Massagué, J. (1994) · Nature · doi:10.1038/370341a0 · Cited by 2,340 · see citing works
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993 · see citing works
Transcriptional control by the TGF‐β/Smad signaling system
Massagué, J., & Wotton, D. (2000) · The EMBO Journal · doi:10.1093/emboj/19.8.1745 · Cited by 1,969 · see citing works
Labelle, M., Begum, S., & Hynes, R. O. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.009 · Cited by 1,833 · see citing works
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109 · see citing works
Bakin, A. V., Tomlinson, A. K., Bhowmick, N. A., Moses, H. L., & Arteaga, C. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005912200 · Cited by 993 · see citing works
Abe, M., Harpel, J. G., Metz, C. N., Nunes, I., Loskutoff, D. J., & Rifkin, D. B. (1994) · Analytical Biochemistry · doi:10.1006/abio.1994.1042 · Cited by 757 · see citing works
Zheng, S. G., Wang, J., Wang, P., Gray, J. D., & Horwitz, D. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2018 · Cited by 597 · see citing works
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression
Ding, Z., Wu, C., Chu, G. C., Xiao, Y., Ho, D. C., Zhang, J., Perry, S. R., Labrot, E., Wu, X., Lis, R. T., et al. (2011) · Nature · doi:10.1038/nature09677 · Cited by 507 · see citing works
Liu, V. C., Wong, L. Y., Jang, T. L., Shah, A. H., Park, I. I., Yang, X. J., Zhang, Q., Lonning, S. M., Teicher, B. A., & Lee, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2883 · Cited by 453 · see citing works
Maeda, M., Johnson, K. R., & Wheelock, M. J. (2005) · Journal of Cell Science · doi:10.1242/jcs.01634 · Cited by 388 · see citing works
Adler, H. L., McCURDY, M. A., Kattan, M. W., Timme, T. L., Scardino, P. T., & Thompson, T. C. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(01)62092-5 · Cited by 387 · see citing works
Cheifetz, S., Hernandez, H., Laiho, M., ten Dijke, P., Iwata, K. K., & Massagué, J. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30535-5 · Cited by 348 · see citing works
Groppe, J. C., Hinck, C. S., Samavarchi‐Tehrani, P., Zubieta, C., Schuermann, J. P., Taylor, A. B., Schwarz, P. M., Wrana, J. L., & Hinck, A. P. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.11.039 · Cited by 284 · see citing works
Self-citationLuo, X., Tarbell, K. V., Yang, H., Pothoven, K. L., Bailey, S. L., Ding, R., Steinman, R. M., & Suthanthiran, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611646104 · Cited by 226 · see citing works
Shariat, S. F., Shalev, M., Menesses-Diaz, A., Kim, I. Y., Kattan, M. W., Wheeler, T. M., & Slawin, K. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2856 · Cited by 215 · see citing works
Wilkes, M. C., Mitchell, H. D., Penheiter, S. G., Doré, J. J. E., Suzuki, K., Edens, M., Sharma, D. K., Pagano, R. E., & Leof, E. B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1522 · Cited by 215 · see citing works
Crystal structure of the human TβR2 ectodomain–TGF-β3 complex
Hart, P. J., Deep, S., Taylor, A. B., Shu, Z., Hinck, C. S., & Hinck, A. P. (2002) · Nature Structural Biology · doi:10.1038/nsb766 · Cited by 214 · see citing works
Self-citationMa, X.-Q., der Made, A. C. J. Z.-V., Autar, B., van der Korput, H. A., Vermeij, M., van Duijn, P. V., Cleutjens, K., de Krijger, R. D., Krimpenfort, P., Berns, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4519 · Cited by 204 · see citing works
Vo, B. T., Morton, D. J., Komaragiri, S. K., Millena, A. C., Leath, C., & Khan, S. A. (2013) · Endocrinology · doi:10.1210/en.2012-2074 · Cited by 192 · see citing works
Kim, I. Y., Ahn, H. J., Zelner, D. J., Shaw, J. W., Sensibar, J. A., Kim, J. H., Kato, M., & Lee, C. (1996) · PubMed · Cited by 191 · see citing works
Viñals, F., & Pouysségur, J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.21.7218-7230.2001 · Cited by 191 · see citing works
Turley, R. S., Finger, E. C., Hempel, N., How, T., Fields, T. A., & Blobe, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3117 · Cited by 181 · see citing works
Shin, I., Bakin, A. V., Rodeck, U., Brunet, A., & Arteaga, C. L. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.11.3328 · Cited by 178 · see citing works
Sawyer, J. S., Beight, D. W., Britt, K. S., Anderson, B. D., Campbell, R. M., Goodson, T. G., III, Herron, D. K., Li, H., McMillen, W. T., Mort, N. A., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.04.007 · Cited by 169 · see citing works
Singh, J., Chuaqui, C. E., Boriack‐Sjodin, P. A., Lee, W., Pontz, T. W., Corbley, M. J., Cheung, H. K., Arduini, R. M., Mead, J. N., Newman, M. N., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.028 · Cited by 167 · see citing works
Radaev, S., Zou, Z., Huang, T., Lafer, E. M., Hinck, A. P., & Sun, P. D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.079921 · Cited by 165 · see citing works
Self-citationProstate tumor progression is mediated by a paracrine TGF-β/Wnt3a signaling axis
Li, X., Placencio, V. R., Iturregui, J. M., Uwamariya, C., Sharif‐Afshar, A., Koyama, T., Hayward, S. W., & Bhowmick, N. A. (2008) · Oncogene · doi:10.1038/onc.2008.293 · Cited by 156 · see citing works
Transforming growth factor-? in benign and malignant prostate
Lee, C., Sintich, S. M., Mathews, E. P., Shah, A. H., KUNDU, S. D., Perry, K. T., Cho, J. S., Ilio, K. Y., Cronauer, M. V., Janulis, L., et al. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19990601)39:4 · Cited by 151 · see citing works
Guo, Y., Jacobs, S. C., & Kyprianou, N. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970516)71:4 · Cited by 129 · see citing works
A positive role for Myc in TGFβ-induced Snail transcription and epithelial-to-mesenchymal transition
Smith, A. P., Verrecchia, A., Fagà, G., Doni, M., Perna, D., Martinato, F., Guccione, E., & Amati, B. B. (2008) · Oncogene · doi:10.1038/onc.2008.395 · Cited by 128 · see citing works
A role for the TGFβ-Par6 polarity pathway in breast cancer progression
Viloria‐Petit, A., David, L., Jia, J., Erdemir, T., Bane, A. L., Pinnaduwage, D., Roncari, L., Narimatsu, M., Bose, R., Moffat, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906796106 · Cited by 128 · see citing works
Expression of transforming growth factor-beta 1 in prostate cancer
Steiner, M. S., Zhou, Z. Z., Tonb, D. C., & Barrack, E. R. (1994) · Endocrinology · doi:10.1210/endo.135.5.7956947 · Cited by 128 · see citing works
Robertson, I. B., & Rifkin, D. B. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.06.003 · Cited by 113 · see citing works
Ao, M., Williams, K., Bhowmick, N. A., & Hayward, S. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4451 · Cited by 110 · see citing works
Targeting TGF-β in prostate cancer: therapeutic possibilities during tumor progression
Jones, E., Pu, H., & Kyprianou, N. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220802705696 · Cited by 107 · see citing works
Assinder, S. J., Dong, Q., Kovačević, Ž., & Richardson, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20081610 · Cited by 94 · see citing works
Williams, R. H., Stapleton, A. M. F., Yang, G., Truong, L. D., Rogers, E., Timme, T. L., Wheeler, T. M., Scardino, P. T., & Thompson, T. C. (1996) · PubMed · Cited by 84 · see citing works
Verona, E. V., ELKAHLOUN, A. G., Yang, J., Bandyopadhyay, A. M., Yeh, I., & Sun, L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0444 · Cited by 71 · see citing works
Self-citationTransforming Growth Factor Beta and Prostate Cancer
Zhu, B., & Kyprianou, N. (2005) · Cancer treatment and research · doi:10.1007/0-387-24361-5_7 · Cited by 68 · see citing works
Stromal TGF-β signaling induces AR activation in prostate cancer
Yang, F., Chen, Y., Shen, T., Guo, D., Dakhova, O., Ittmann, M., Creighton, C. J., Zhang, Y., Dang, T. D., & Rowley, D. R. (2014) · Oncotarget · doi:10.18632/oncotarget.2536 · Cited by 48 · see citing works
Bjerke, G. A., Yang, C.-S., Frierson, H. F., Paschal, B. M., & Wotton, D. (2013) · Oncogene · doi:10.1038/onc.2013.342 · Cited by 32 · see citing works
Solution Structure and Backbone Dynamics of the TGFβ Type II Receptor Extracellular Domain,
Deep, S., Walker, K. P., Shu, Z., & Hinck, A. P. (2003) · Biochemistry · doi:10.1021/bi034366a · Cited by 29 · see citing works
Self-citationTGF-β signalling and immunity in prostate tumourigenesis
Diener, K. R., Need, E. F., Buchanan, G., & Hayball, J. D. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903544507 · Cited by 23 · see citing works
Characterization of PacMetUT1, a recently isolated human prostate cancer cell line
Troyer, D. A., Tang, Y., Bedolla, R. G., Adhvaryu, S. G., Thompson, I. M., Abboud‐Werner, S. L., Sun, L., Friedrichs, W. E., & deGraffenried, L. A. (2008) · The Prostate · doi:10.1002/pros.20758 · Cited by 21 · see citing works
Self-citationGowda, P. S., Deng, J. D., Mishra, S., Bandyopadhyay, A. M., Liang, S., Lin, S., Mahalingam, D., & Sun, L. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0278 · Cited by 20 · see citing works
Self-citationExpression, purification and characterization of BGERII: a novel pan-TGF inhibitor
Verona, E. V., Tang, Y., Millstead, T. K., Hinck, A. P., Agyin, J. K., & Sun, L. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn023 · Cited by 17 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works
Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer
Watt, M. J., Clark, A. K., Selth, L. A., Haynes, V. R., Lister, N. L., Rebello, R. J., Porter, L. H., Niranjan, B., Whitby, S., Lo, J. C. Y., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5758 · Cited by 324 · see citing works
A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment
Huynh, L., Hipolito, C. J., & ten Dijke, P. (2019) · Biomolecules · doi:10.3390/biom9110743 · Cited by 172 · see citing works
The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?
Gonzalez‐Sanchez, E., Vaquero, J., Fernández‐Barrena, M. G., Lasarte, J. J., Avila, M. A., Sarobe, P., Reig, M., Calvo, M., & Fabregat, I. (2021) · Cancers · doi:10.3390/cancers13133248 · Cited by 95 · see citing works
Using human genetics to improve safety assessment of therapeutics
Carss, K., Deaton, A. M., Río-Espínola, A. D., Diogo, D., Fielden, M. R., Kulkarni, D. A., Moggs, J. G., Newham, P., Nelson, M. R., Sistare, F. D., et al. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00561-w · Cited by 88 · see citing works
Transforming growth factor-β receptors: versatile mechanisms of ligand activation
Chia, Z. J., Cao, Y.-N., Little, P. J., & Kamato, D. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01235-6 · Cited by 92 · see citing works
Transforming growth factor-beta (TGF-β) in prostate cancer: A dual function mediator?
Mirzaei, S., Paskeh, M. D. A., Saghari, Y., Zarrabi, A., Hamblin, M. R., Entezari, M., Hashemi, M., Aref, A. R., Hushmandi, K., Kumar, A. P., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.02.094 · Cited by 74 · see citing works
Cancer stem cell in prostate cancer progression, metastasis and therapy resistance
Verma, P., Shukla, N., Kumari, S., Ansari, M. S., Gautam, N. K., & Patel, G. K. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188887 · Cited by 65 · see citing works
Zhu, H., Gu, X. Q., Xia, L., Zhou, Y., Bouamar, H., Yang, J., Ding, X., Zwieb, C. W., Zhang, J., Hinck, A. P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3112 · Cited by 64 · see citing works
Self-citationLudwig, N., Yerneni, S. S., Azambuja, J. H., Pietrowska, M., Widłak, P., Hinck, C. S., Głuszko, A., Szczepański, M. J., Kärmer, T., Kallinger, I., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12294 · Cited by 55 · see citing works
Self-citationTakahashi, K., Akatsu, Y., Podyma‐Inoue, K. A., Matsumoto, T., Takahashi, H., Yoshimatsu, Y., Koinuma, D., Shirouzu, M., Miyazono, K., & Watabe, T. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012492 · Cited by 52 · see citing works
Chruścik, A., Gopalan, V., & Lam, A. K.-Y. (2017) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2017.11.001 · Cited by 51 · see citing works
Wang, J., Wang, W., Cai, H., Du, B., Mai, P., Zhang, L., Ma, W., Hu, Y., Feng, S.-F., & Miao, G. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s160831 · Cited by 48 · see citing works
RetractedMurad, J. P., Christian, L., Rosa, R. C. A., Ren, Y., Buckley, A. J., Lee, E. H. J., Lopez, L. S., Park, A. K., Yang, J., Yamaguchi, Y., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01509-2 · Cited by 50 · see citing works
Self-citationTherapeutic Implications of TGFβ in Cancer Treatment: A Systematic Review
Gómez‐Gil, V. (2021) · Cancers · doi:10.3390/cancers13030379 · Cited by 32 · see citing works
Regulatory T Cells in the Tumor Microenvironment
Dadey, R., Workman, C. J., & Vignali, D. A. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_6 · Cited by 30 · see citing works
Alterations in TGFβ signaling during prostate cancer progression.
Elliott, B., Johnson, R., & Khan, S. A. (2021) · Europe PMC (PubMed Central) · Cited by 30 · see citing works
Ludwig, N., Wieteska, Ł., Hinck, C. S., Yerneni, S. S., Azambuja, J. H., Bauer, R. J., Reichert, T. E., Hinck, A. P., & Whiteside, T. L. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0944 · Cited by 28 · see citing works
Self-citationAnoikis in phenotypic reprogramming of the prostate tumor microenvironment
Nepali, P. R., & Kyprianou, N. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1160267 · Cited by 27 · see citing works
Small extracellular vesicle TGF-β in cancer progression and immune evasion
Hosseini, R., Hosseinzadeh, N., Asef‐Kabiri, L., Akbari, A., Ghezelbash, B., Sarvnaz, H., & Akbari, M. E. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00638-7 · Cited by 23 · see citing works
Kodama, S., Podyma‐Inoue, K. A., Uchihashi, T., Kurioka, K., Takahashi, H., Sugauchi, A., Takahashi, K., Inubushi, T., Kogo, M., Tanaka, S., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.8148 · Cited by 22 · see citing works
Pollard, B. S., Suckow, M. A., Wolter, W. R., Starr, J. M., Eidelman, O., Dalgard, C. L., Kumar, P., Battacharyya, S., Srivastava, M., Biswas, R., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00630 · Cited by 16 · see citing works
Zhou, C., Li, J., Lin, L., Shu, R., Dong, B., Cao, D., Li, Q., & Wang, Z. (2018) · Oncotarget · doi:10.18632/oncotarget.24562 · Cited by 14 · see citing works
Kim, S. K., Whitley, M. J., Krzysiak, T. C., Hinck, C. S., Taylor, A. B., Zwieb, C. W., Byeon, C., Zhou, X., Mendoza, V., López‐Casillas, F., et al. (2019) · Structure · doi:10.1016/j.str.2019.06.010 · Cited by 14 · see citing works
Self-citationEvidence of the Link between Stroma Remodeling and Prostate Cancer Prognosis
Vecchiotti, D., Clementi, L., Cornacchia, E., Nolfi, M. D. V., Verzella, D., Capece, D., Zazzeroni, F., & Angelucci, A. (2024) · Cancers · doi:10.3390/cancers16183215 · Cited by 12 · see citing works
Functionally diverse heteromeric traps for ligands of the transforming growth factor-β superfamily
Kumar, R., Grinberg, A. V., Li, H., Kuo, T., Sako, D., Krishnan, L., Liharska, K., Li, J., Grenha, R., Maguire, M. C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97203-9 · Cited by 11 · see citing works
Wodziński, D., Wosiak, A., Pietrzak, J., Świechowski, R., Kordek, R., & Balcerczak, E. I. (2022) · Scientific Reports · doi:10.1038/s41598-022-15599-4 · Cited by 11 · see citing works
Roles of TGF-β in cancer hallmarks and emerging onco-therapeutic design
Dai, X., Hua, D., & Lu, X. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.37 · Cited by 10 · see citing works
Beneficial effect of KYP-2047, a propyl-oligopeptidase inhibitor, on oral squamous cell carcinoma
Scuderi, S. A., Casili, G., Filippone, A., Lanza, M., Basilotta, R., Giuffrida, R., Munaò, S., Colarossi, L., Capra, A. P., Esposito, E., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.28147 · Cited by 8 · see citing works
Nanomedicine for the Treatment of Advanced Prostate Cancer
Vicente‐Ruiz, S., Serrano‐Martí, A., Armiñán, A., & Vicent, M. J. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000136 · Cited by 7 · see citing works
Wu, B. X., Kreatsoulas, D. C., Çam, H., Bolyard, C. M., Chang, Y., Mandula, J. K., Welsh, P. W., Wang, Z., Li, A., Weltge, P., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf195 · Cited by 6 · see citing works
Autocrine TGFβ2 enforces a transcriptionally hybrid cell state in Ewing sarcoma
Wrenn, E. D., Harris, J. C., Apfelbaum, A. A., Valenti, J. R., Lipson, P. A., Walter, S. I., Garcia, N. M., Miyaki, A., Chen, S. C., Olson, J. M., et al. (2026) · Science Advances · doi:10.1126/sciadv.ady0550 · Cited by 5 · see citing works
Th1 differentiation and function are inhibited in neonates following human metapneumovirus infection
Brown, E., Lan, J., Parks, O. B., Hinck, C. S., Hinck, A. P., Williams, J. V., & Eddens, T. J. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf057 · Cited by 5 · see citing works
Self-citationDaley, J. D., Mukherjee, E., Ferraro, D., Tufino, A. C., Bailey, N. G., Bhaskar, S., Periyapatna, N., MacFawn, I., Hartwick, S., Kunning, S. R., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0346 · Cited by 5 · see citing works
Self-citationAlabi, F. A., Okpalanwaka, I. F., Oyegbesan, A., Okoyeocha, E. O. M., Oladejo, M., & Imodoye, S. O. (2025) · MedComm – Oncology · doi:10.1002/mog2.70027 · Cited by 3 · see citing works
Daley, J. D., Mukherjee, E., Tufino, A. C., Bailey, N. G., Bhaskar, S., Periyapatna, N., MacFawn, I., Kunning, S. R., Hinck, C. S., Bruno, T. C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.07.592974 · Cited by 3 · see citing works
Self-citationTGF-β Signaling Pathway and Its Therapeutic Role in Cancer
James, A. W., Bhat, H. M., Yousuf, S., Jan, M., Rehman, M. U., & Rashid, S. M. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_11 · Cited by 1 · see citing works
Prostate Cancer and Inflammation
Hashemi, M., Tavakolipour, V., Morovatshoar, R., Samadpour, A., Asheghabadi, P. S., Hadadian, H., Bandsariyan, A., Ghasemi, Z., Orouei, S., AbolfathyNajmabady, N., et al. (2024) · Springer eBooks · doi:10.1007/978-981-97-4612-5_3
TGF-β in tumor microenvironment, metabolism, and immunotherapy
Bai, H., & Wan, Y. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13827-0.00017-2
Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 deliveryPreprint
Murad, J. P., Christian, L., Rosa, R. C. A., Ren, Y., Lee, E., Lopez, L. S., Park, A. J., Yang, J., Trac, C., Adkins, L. N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.04.647304
Self-citation
- Authors
- Qin, T., Barron, L., Xia, L., Huang, H., Villarreal, M. M., Zwaagstra, J., Collins, C., Yang, J., Zwieb, C., Kodali, R., Hinck, C. S., Kim, S. K., Reddick, R. L., Shu, C., O’Connor-McCourt, M. D., Hinck, A. P., & Sun, L.-Z.
- Affiliations
- Central South University (CN)
- The University of Texas at San Antonio Health Science Center (US)
- Mayo Clinic (US)
- National Research Council Canada (CA)
- University of Pittsburgh (US)
- National Research Council Human Health Therapeutics Portfolio, Montréal, Quebec, Canada, Maureen O'Connor-McCourt is currently affiliated with Formation Biologics, Montréal, Quebec, Canada
- ORCID
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-11-14
- Volume
- 7
- Issue
- 52
- Pages
- 86087-86102
- ISSN
- 1949-2553 (ISSN-L)
- PMC
- PMC5349899
- OpenAlex
- W2549892900
- Cited by
- 40
- References
- 49
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 5 · 2023: 3 · 2022: 5 · 2021: 7 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 1
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Oncotarget (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Central South University
- National Institutes of Health (CA054174)
- National Cancer Institute (CA-054174, P30CA054174, R01CA172886, P30CA015083)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- RER, prostate cancer, tumor invasion, TGF-beta signaling, tumor suppressor, tumor promoters, tumor cell adhesion, tumor cell proliferation
- MeSH terms
- Animals, Humans, Male, Neoplasm Invasiveness, Neoplasm Staging, Phosphorylation, Prostate, Prostatic Neoplasms, Signal Transduction, Receptors, Transforming Growth Factor beta, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Mice, Smad Proteins, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
